Vanda Pharma Inc v. Alembic Pharma Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Vanda Pharmaceuticals Inc. (Delaware)
  • Defendant: Alembic Pharmaceuticals Limited (India) and Alembic Pharmaceuticals, Inc. (Delaware)
  • Plaintiff's Counsel: McCarter & English, LLP
• Case Identification: 1:26-cv-00905, D. Del., 07/24/2026
• Venue Allegations: Venue is alleged to be proper as to Alembic Pharmaceuticals, Inc. because it is incorporated in Delaware. Venue is alleged to be proper as to Alembic Pharmaceuticals Limited as it is a foreign defendant that has previously consented to venue in the district.
• Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's FANAPT® (iloperidone) tablets constitutes an act of infringement of a patent covering a method of administering the drug based on a patient's genetic profile.
• Technical Context: The technology involves pharmacogenomics, specifically tailoring the dosage of the antipsychotic drug iloperidone based on a patient's status as a "poor metabolizer" of the CYP2D6 enzyme to mitigate safety risks.
• Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following Plaintiff's receipt of a Notice Letter from Defendants. The letter stated that Defendants had filed an ANDA with a Paragraph IV certification, asserting that U.S. Patent No. 8,586,610, which is listed in the FDA's Orange Book for FANAPT®, is invalid, unenforceable, and/or not infringed by the proposed generic product.

Case Timeline

Date	Event
2004-09-30	'610 Patent Priority Date
2009-05-06	Vanda's FANAPT® receives initial FDA approval
2013-11-19	'610 Patent Issue Date
2024-04-02	FDA approves supplemental indication for FANAPT®
2026-06-11	Plaintiff receives Defendants' ANDA Notice Letter
2026-07-24	Complaint Filing Date
2027-11-02	'610 Patent Expiration Date (as alleged in complaint)

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,586,610 - "Methods for the Administration of Iloperidone"

• Patent Identification: U.S. Patent No. 8,586,610 ("Methods for the Administration of Iloperidone"), issued November 19, 2013 (the "'610 Patent").

The Invention Explained

• Problem Addressed: The patent addresses the risk that patients with certain genetic variations metabolize drugs at different rates Compl. ¶35 Specifically, individuals who are "poor metabolizers" due to polymorphisms in the CYP2D6 gene may experience increased concentrations of a drug like iloperidone, which can lead to dangerous physiological effects, such as prolongation of the electrocardiographic QT interval '610 Patent, col. 1:21-28 '610 Patent, col. 1:50-53
• The Patented Solution: The patent discloses a method of personalized medicine. The method involves first determining if a patient has a "CYP2D6 poor metabolizer genotype" through a genotyping assay '610 Patent, col. 2:45-50 If the patient is identified as a poor metabolizer, they are administered a reduced dosage of iloperidone (12 mg/day or less) to avoid adverse effects. Patients without this genotype receive a standard, higher dose (up to 24 mg/day) '610 Patent, claim 1 This dose-adjustment strategy is intended to provide a safer treatment regimen tailored to the patient's genetic makeup '610 Patent, col. 9:30-45
• Technical Importance: The invention provides a clinical application of pharmacogenomics, allowing physicians to proactively adjust drug dosage based on a patient's genetic profile to enhance safety, a significant step beyond one-size-fits-all prescribing. '610 Patent, col. 2:15-24

Key Claims at a Glance

• The complaint asserts infringement of at least Claim 1 of the '610 Patent Compl. ¶46
• The essential elements of independent claim 1 include:
  • A method for treating a patient with iloperidone for schizophrenia.
  • Determining if the patient is a CYP2D6 poor metabolizer by obtaining a biological sample and performing a genotyping assay to identify a "CYP2D6 poor metabolizer genotype."
  • If the patient has the poor metabolizer genotype, internally administering iloperidone at a dose of 12 mg/day or less.
  • If the patient does not have the poor metabolizer genotype, internally administering iloperidone at a dose greater than 12 mg/day (up to 24 mg/day).
• The complaint does not explicitly reserve the right to assert dependent claims but alleges infringement of "at least one claim" and "one or more claims" Compl. ¶47 Compl. ¶49

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Defendants' proposed generic version of FANAPT® (iloperidone) oral tablets, which is the subject of ANDA No. 207409 ("Alembic's ANDA Product") Compl. Introduction The product is intended to be bioequivalent to FANAPT® and will be offered in the same strengths Compl. ¶29 Compl. ¶30

Functionality and Market Context

• The infringement allegation centers on the proposed labeling for Alembic's ANDA Product. The complaint alleges that this label, which is required by law to be substantively similar to the brand-name FANAPT® label, will instruct and encourage physicians to practice the patented method Compl. ¶37 Compl. ¶41 Compl. ¶48 Specifically, the complaint alleges the label will encourage physicians to test patients for their CYP2D6 metabolizer status and then administer a halved dosage (12 mg per day) to poor metabolizers, while administering the full target dosage (up to 24 mg per day) to normal metabolizers Compl. ¶39 Compl. ¶40 The complaint attaches as Exhibit A the Prescribing Information for FANAPT®, which it alleges will be substantively copied by the accused product's label Compl. ¶22 Compl. ¶41

IV. Analysis of Infringement Allegations

'610 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for treating a patient with iloperidone, wherein the patient is suffering from schizophrenia...	Alembic's proposed label will indicate its iloperidone product for the treatment of schizophrenia.	¶42	col. 17:1-3
determining whether the patient is a CYP2D6 poor metabolizer by: obtaining or having obtained a biological sample from the patient; and performing or having performed a genotyping assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype;	Alembic's proposed label will actively encourage physicians to determine a patient's CYP2D6 status by obtaining a biological sample and performing a genotyping assay.	¶39	col. 17:4-10
if the patient has a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount of 12 mg/day or less,	Alembic's proposed label will encourage physicians to administer a halved dosage amount to poor metabolizers, reducing the maximum target dose from 24 mg per day to 12 mg per day.	¶40	col. 17:11-14
and if the patient does not have a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day,	Alembic's proposed label will encourage physicians to administer the normal target dosage amount (implied to be greater than 12 mg/day) if the patient is a normal CYP2D6 metabolizer.	¶40	col. 17:15-19

• Identified Points of Contention:
  • Scope Questions: A potential dispute may arise over whether the instructions on Alembic's proposed label rise to the level of active inducement required by 35 U.S.C. § 271(b). The court will have to determine if the label's language "actively encourages" infringement, as the complaint alleges Compl. ¶39, or merely provides information that falls short of the legal standard for inducement.
  • Legal Questions: The method claim involves steps that may be performed by different parties (e.g., a physician prescribing, a lab conducting the assay, a patient self-administering). This raises the question of divided infringement. A central issue will be whether the actions of a prescribing physician-ordering a test, reviewing the results, and prescribing a specific dose-are sufficient to constitute direct infringement of the entire method, particularly given the claim's use of "obtaining or having obtained" and "performing or having performed" language.

V. Key Claim Terms for Construction

• The Term: "CYP2D6 poor metabolizer genotype"

• Context and Importance: This term is the lynchpin of the claimed method, as it defines the specific patient population for whom the dose must be adjusted. The breadth of this definition will determine the scope of infringement and may also be relevant to validity challenges.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The claim language itself is not limited to specific genetic alleles. The specification supports a functional definition, referring generally to "polymorphisms ... associated with poor metabolizing status" '610 Patent, col. 4:25-27 and genotypes that result in "decreased activity of the CYP2D6 protein" '610 Patent, col. 11:36-39 Plaintiff may argue the term covers any genotype known to cause a poor metabolizer phenotype.
  • Evidence for a Narrower Interpretation: The detailed description focuses heavily on specific alleles, such as "CYP2D6G1846A" and "CYP2D6P34S" '610 Patent, col. 5:6-22 Dependent claims 3-6 explicitly recite these specific genotypes. A defendant may argue that the invention is limited to these disclosed genotypes and that the term should be construed narrowly to encompass only them or their equivalents.

• The Term: "determining"

• Context and Importance: This term is critical to the divided infringement analysis. Practitioners may focus on this term because its construction will clarify which actor-the physician, the laboratory, or both-performs the key diagnostic step of the claimed method.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The surrounding claim language "obtaining or having obtained" and "performing or having performed" a genotyping assay suggests that the "determining" step is accomplished by the single actor who synthesizes the information, i.e., the physician who orders the test and uses the result to guide treatment '610 Patent, claim 1
  • Evidence for a Narrower Interpretation: A defendant may argue that the entity that physically "perform[s]" the genotyping assay is the one that "determin[es]" the genotype. Under this reading, if a laboratory performs the assay and a physician prescribes the drug, no single entity performs all claim steps, potentially negating a finding of direct infringement.

VI. Other Allegations

• Indirect Infringement: The complaint's primary theory is indirect infringement. It alleges induced infringement under 35 U.S.C. § 271(b), asserting that Alembic, by seeking approval for a product with its proposed label, knows and intends for prescribers to follow those instructions and thereby infringe the '610 patent Compl. ¶49 It also alleges contributory infringement under 35 U.S.C. § 271(c), stating that Alembic's generic iloperidone tablets are a material part of the invention, are not a staple article of commerce, and will be sold with knowledge of their infringing use Compl. ¶50
• Willful Infringement: The complaint does not contain an explicit allegation of "willful infringement." However, it alleges that Alembic has knowledge of the '610 patent and its infringement, based on the filing of the ANDA and the associated Paragraph IV certification Compl. ¶26 Compl. ¶49, which could form the basis for such a claim later in the proceedings.

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of inducement: Does the language of Alembic's proposed product label, which is required to mirror the brand-name label, cross the legal threshold from merely providing information to actively encouraging or instructing physicians to perform the patented dose-adjustment method?
• A second key question will be one of divided infringement: Can Vanda establish that a single actor, such as the prescribing physician, can be held liable for direct infringement of the method claim by ordering and interpreting a genetic test and subsequently prescribing the drug, even when a separate laboratory performs the assay itself? The construction of "determining" in the context of the "having performed" claim language will be decisive.
• Finally, the case may turn on a question of claim scope: How will the court construe the term "CYP2D6 poor metabolizer genotype"? A narrow construction limited to the specific alleles disclosed in the patent could limit the scope of infringement, while a broader, more functional definition could strengthen the infringement case but potentially expose the claim to validity challenges based on a wider body of prior art.